Dr. Ann R. Falsey, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 30
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Vanderbilt University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
NY license 174572
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
Medical groups
- Infectious Disease Clinical (45 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 30
- Services billed
- 57
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 30 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 5 companies reported 17 payments worth $33,720 in total to this clinician.
| Sanofi Pasteur Inc. | $27,954 |
|---|---|
| AstraZeneca UK Limited | $4,095 |
| GlaxoSmithKline, LLC. | $1,489 |
| Astellas Pharma US Inc | $99.95 |
| Adma Biomanufacturing LLC | $81.90 |
| Compensation for services other than consulting (speaking, faculty) | $18,029 |
|---|---|
| Travel and Lodging | $11,040 |
| Consulting Fee | $4,095 |
| Food and Beverage | $456 |
| Education | $99.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi Pasteur Inc. Oct 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $18,029 |
| Sanofi Pasteur Inc. Oct 18, 2025 | Travel and Lodging travel to Valencia, Spain · in-kind | $8,767 |
| AstraZeneca UK Limited Mar 18, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,095 |
| Sanofi Pasteur Inc. Oct 18, 2025 | Travel and Lodging travel to Valencia, Spain · in-kind | $833 |
| GlaxoSmithKline, LLC. Oct 28, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $816 |
| Sanofi Pasteur Inc. Oct 18, 2025 | Travel and Lodging travel to Valencia, Spain · in-kind | $277 |
| GlaxoSmithKline, LLC. Nov 13, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $185 |
| GlaxoSmithKline, LLC. Nov 14, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $132 |
| Astellas Pharma US Inc Jan 2, 2025 | Education in-kind | $99.95 |
| GlaxoSmithKline, LLC. Oct 28, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $31.41 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $542,441 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ModernaTX, Inc. · Completed · NCT06067230 - LRTI Secondary Analysis for RSV and Hmpv
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.